Immunocore Holdings annual stock-based compensation
2021
2022
2023
2024
2025
Immunocore Holdings Stock-Based Compensation Growth & History (IMCR)
Immunocore Holdings's stock-based compensation was $37.7M for fiscal 2025.
View full Immunocore Holdings company overviewImmunocore Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $37.7M | $3.5M | +10.26% |
| 2024 | 2024-12-31 | $34.2M | $1.7M | +5.30% |
| 2023 | 2023-12-31 | $32.5M | −$419,000 | −1.27% |
| 2022 | 2022-12-31 | $32.9M | −$16.0M | −32.74% |
| 2021 | 2021-12-31 | $48.9M | — | — |
Immunocore Holdings quarterly stock-based compensation
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.4M | −$629,000 | −6.27% |
| Q1 2026 | 2026-03-31 | $6.3M | −$3.2M | −33.59% |
| Q4 2025 | 2025-12-31 | $8.3M | −$328,000 | −3.78% |
| Q3 2025 | 2025-09-30 | $9.8M | $3.3M | +49.98% |
| Q2 2025 | 2025-06-30 | $10.0M | $33,000 | +0.33% |
| Q1 2025 | 2025-03-31 | $9.5M | $525,000 | +5.86% |
| Q4 2024 | 2024-12-31 | $8.7M | $1.5M | +20.53% |
| Q3 2024 | 2024-09-30 | $6.6M | −$1.6M | −20.00% |
| Q2 2024 | 2024-06-30 | $10.0M | $1.2M | +13.37% |
| Q1 2024 | 2024-03-31 | $9.0M | $706,000 | +8.55% |
| Q4 2023 | 2023-12-31 | $7.2M | — | — |
| Q3 2023 | 2023-09-30 | $8.2M | — | — |
| Q2 2023 | 2023-06-30 | $8.8M | — | — |
| Q1 2023 | 2023-03-31 | $8.3M | — | — |
Immunocore Holdings stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Immunocore Holdings's stock-based compensation decreased from $48.9M to $37.7M, a change of −$11.2M. The latest reported quarter, Q2 2026, shows $9.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunocore Holdings source filings ↗